Compare Sanofi SA (SNY) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Western Union Co — how do they compare? Sanofi SA trades at $40.01 (market cap $95.18B), while Western Union Co trades at $6.25 (market cap $1.97B). The key difference: Sanofi SA is far larger — about 48.3× Western Union Co's market cap, and Western Union Co pays the higher dividend (14.85%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Western Union Co for 95 Days on average.
| SNY | WU | |
|---|---|---|
Market Cap | $95.18B | $1.97B |
Volume | 2,995,646 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $52.34 | $10.28 |
52-Week Low | $39.51 | $5.90 |
Typical Hold Time | 94 Days | 95 Days |
Enterprise Value | $114.48B | $1.88B |
Dividend Yield | 6.01% | 14.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Western Union (WU) trades at $6.11, down 0.49% on the day, with the stock showing bearish technical signals and mixed fundamental performance. Recent earnings show two misses in the last three quarters, though the company maintains strong profitability metrics including a 43.97% ROE and 9.79% net margin. The $200 million Beyond Efficiency Plan aims to revive profitability by 2027, while the pending Intermex acquisition faces regulatory hurdles in California.
WU presents a value opportunity with low P/E (5.1) and P/S (0.5) ratios, but faces execution risks from margin pressures and acquisition integration. Analyst consensus is cautious with a $6.86 price target, representing 12% upside, though recent technical weakness and earnings volatility warrant careful monitoring of the turnaround plan's progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
